Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Regeneron Pharmaceuticals Inc

REGN

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Last trade $956.99
Day change +$4.59 (+0.48%)
Day range $948.25 – $965.57
Volume 354,318
Market cap $98.52B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$98.52B
Price / earnings
20.45×
Price / book
2.94×
Price / sales
5.83×
EV / sales
5.77×
EV / EBITDA
18.18×

Profitability

Earnings per share
$46.57
Return on assets
10.85%
Return on equity
14.38%
Dividend yield
0.39%

Liquidity and leverage

Debt / equity
0.08×
Current ratio
3.35×
Quick ratio
2.89×
Cash ratio
0.59×

Cash flow

Price / cash flow
20.33×
Price / free cash flow
25.75×
Free cash flow
$3.83B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for REGN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$5.12B$4.29B$3.61B$3.88B$3.75B$3.68B$3.03B$3.79B
Cost of revenue$573.6M$576.5M$669.4M$584.6M$521.6M$530.2M$464.3M$565.4M
Gross profit$4.54B$3.71B$2.94B$3.3B$3.23B$3.15B$2.56B$3.22B
Selling, general and administrative$677.8M$662.1M$647.7M$775M$657.8M$634.2M$633M$792.2M
Research and development$1.82B$1.76B$1.65B$1.64B$1.56B$1.43B$1.34B$1.43B
Total operating expenses$2.49B$2.42B$2.29B$2.43B$2.21B$2.07B$1.97B$2.18B
Operating income$2.05B$1.29B$642.9M$869.9M$1.03B$1.08B$591.7M$1.04B
Interest expense-$10.6M-$11M-$12.9M-$12.2M-$19.3M-$3.6M-$8.7M-$10.5M
Income before taxes$2.28B$1.53B$831.2M$1.04B$1.76B$1.52B$905M$958.1M
Income taxes$335.4M$230.9M$104M$199.1M$303.3M$127.1M$96.3M$40.4M
Net income$1.95B$1.3B$727.2M$844.6M$1.46B$1.39B$808.7M$917.7M
Net income attributable to common shareholders$1.95B$1.3B$727.2M$844.6M$1.46B$1.39B$808.7M$917.7M
EBITDA$2.17B$1.42B$766.1M$1.01B$1.16B$1.21B$718.6M$1.17B
Basic earnings per share$19.16$12.62$6.99$8.20$14.09$13.24$7.58$8.53
Diluted earnings per share$18.45$12.23$6.75$7.86$13.62$12.81$7.27$8.07

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

The Motley Fool

Better Biotech ETF: First Trust's FBT vs. Invesco's PBE

First Trust's FBT and Invesco's PBE are compared as primary vehicles for biotech sector exposure. FBT offers lower fees (0.55% vs 0.59%), higher AUM ($3.0B vs $438M), and stronger 1-year returns (35.7% vs 28.1%), while PBE provides dividend income and uses a multi-factor quantitative approach. The choice depends on investor priorities regarding cost, liquidity, and investment strategy.

The Motley Fool

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

Regeneron Pharmaceuticals is highlighted as potentially the cheapest major biotech company, trading at approximately 21x trailing earnings with $16 billion in net cash. The company's stock has climbed over 40% in the past year, driven by strong performance from key products like Libtayo and Eylea HD, which posted record sales. With a robust pipeline of 50 candidates and a $1 billion upfront payment from an expanded Sanofi partnership, Regeneron appears well-positioned for future growth.

Zacks Investment Research

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences reported a Q3 2026 loss of $1.05 per share, wider than expected, as R&D expenses rose 15.5% year-over-year. However, the company announced positive phase III DAYBREAK study results for lead candidate Zenkuda and KSI-501, both meeting primary endpoints against Regeneron's Eylea. Kodiak plans to submit a BLA for Zenkuda by year-end and expects KSI-101 data in December 2026.

GlobeNewswire Inc.

BCMA Targeted Therapies Competitive Landscape Analysis: 100+ Pipeline Therapies Driving Innovation in Therapeutics Segment | DelveInsight

DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.94 per share
Declared
Oct 30, 2026
Ex-dividend
Nov 20, 2026
Pay date
Dec 3, 2026
Ex-dividendAmount / sharePay dateType
Aug 18, 2026$0.94Aug 31, 2026recurring
May 20, 2026$0.94Jun 4, 2026recurring
Feb 20, 2026$0.94Mar 5, 2026recurring
Nov 20, 2025$0.88Dec 5, 2025recurring
Aug 18, 2025$0.88Sep 3, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.